In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.

Cells treated with ibrutinib and acalabrutinib each had a unique set of 13 m/z signals, which opens up the possibility of studying these metabolites as biomarkers of therapeutic response.

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

在AMPLIFY临床试验中，研究人员纳入了包括27个国家的800多名从未治疗的CLL患者，并将给予化疗的疗法与新型全药片疗法进行比较研究；针对CLL的标准化疗策略加上免疫疗法利妥昔单抗（rituximab）需要患者进行长时间的注射，并可能会引起长期的免疫抑制和其它令人不愉快的副作用发生。研究者John ...

本研究首次描述了非洲血统 CLL 患者的白血病遗传和转录组特征。与欧洲血统 CLL 相比，非洲血统 CLL 具有更高的基因组复杂性，BRCC3、NOTCH1、NXF1 和 NFKBIE 等基因的突变患病率增加，同时存在 NF - κB 信号转录富集和端粒侵蚀增加的现象。

Risk factors for chronic lymphocytic leukemia (CLL) include having a family history of CLL, being over the age of 50, exposure to certain chemicals, your biological sex, and your race. Chronic ...

Introduction: A unique feature of chronic lymphocytic leukemia (CLL) is the increased number of circulating T cells preventing malignant B cells from undergoing apoptosis. Dysregulated expression of ...

In this video, Jennifer A. Woyach, MD, discusses results from the AMPLIFY trial, presented at ASH Annual Meeting and Exhibition.The trial evaluated fixed-duration acalabrutinib (Calquence, AstraZeneca ...

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, with disease progression ranging from slow and indolent to ...

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...